How many blood-based biomarkers are we actually looking at when it comes to neurodegenerative dementia?

There's more to these tests than meets the eye, especially with the evolving role of genetic tests like apolipoprotein E status.

For years, it was believed there was no point in checking these genetic markers, as there was nothing actionable to offer.

But times have changed, and so has the approach to these tests.

So, what does this mean for the future of diagnosing and managing dementia?

Amy E. Sandersis a neurologist.

SUBSCRIBE TO THE PODCAST https://www.kevinmd.com/podcast